



MISSISSIPPI DIVISION OF
MEDICAID

**MISSISSIPPI DIVISION OF MEDICAID
Pharmacy & Therapeutics Committee Meeting**

Woolfolk Building
Conference Center East, Room 145
Jackson, MS 39201-1399

**November 2, 2017
9:00am to 5:00pm**

MINUTES

Committee Members Present:

John Cook, M.D.
D. Stanley Hartness, M.D.
Deborah Minor, Pharm.D.
Jason Parham, M.D.
Spencer Sullivan, MD
Geri Lee Weiland, M.D.
Wilma Wilbanks, R.Ph.

Committee Members Not Present:

Jeffrey A. Ali, M.D., M.Sc.
Steven V. Dancer, R.Ph.
Logan Davis, Pharm.D., MBA
Naznin Dixit, M.D.
Brent Lindley, PharmD

Division of Medicaid Staff Present:

Terri Kirby, R.Ph., Pharmacy Director
Cindy Noble, Pharm.D., MPH, Pharmacist III
Gail C. McCorkle, R.Ph., Pharmacist III
Dorthy Young, Ph.D., Deputy Director of
Health Services
Chris A. Yount, MA, PMP, Staff Officer III

Contract Staff/GHS Staff Present:

Chad Bissell, Pharm.D., MBA
Laureen Biczak, D.O.
Paige Clayton, Pharm.D.
Shannon Hardwick, R.Ph.

Other Contract Staff Present:

Karen Powell, Pharm.D., Conduent
Lew Anne Snow, R.N., Conduent
Leslie Leon, Pharm.D., Conduent
Eric Pittman, Pharm.D., UM School of
Pharmacy

Committee Attendance for SFY 2018

	AUG 2017	NOV 2017	FEB 2018	MAY 2018
Ali	x			
Cook		x		
Dancer				
Davis				
Dixit				
Hartness	x	x		
Lindley	x			
Minor	x	x		
Parham	x	x		
Sullivan	x	x		
Weiland		x		
Wilbanks	x	x		

I. Call to Order

Ms. Wilma Wilbanks, Chairperson, called the meeting to order at 9:04 a.m.

II. Introductions

Ms. Terri Kirby, Mississippi Division of Medicaid (DOM) Pharmacy Director, welcomed the Pharmacy & Therapeutics (P&T) Committee and all guests in the audience.

She introduced Change Healthcare, DOM's Preferred Drug List (PDL) and Supplemental Rebate (SR) vendor. All parties seated at the table introduced themselves and gave a brief statement about their professional credentials and affiliations.

Ms. Kirby introduced DOM staff members Chris Yount, and Jessica Tyson. Ms. Kirby recognized DOM contractors in the audience, including Drs. Leslie Leon, Karen Powell and Lew Anne Snow from Conduent, Dr. Eric Pittman from the University of the Mississippi School of Pharmacy's MS-DUR Program and Shannon Hardwick, RPh from Change Healthcare.

III. Administrative Matters

Ms. Kirby reminded guests to sign in via the electronic process available through the DOM website (www.medicaid.ms.gov) prior to the meeting. She stated that copies of the agenda and the public comment guidelines are available at the sign-in table. She stated that there is a separate sign in sheet for advocates and reminded guests that advocate presenters are limited to 5 minutes of general comment about a disease, not specific to a drug. She noted that industry presenters must provide their full name, drug name, identification, and company affiliation when signing in. She stated that industry

presenters are allowed 3 minutes per drug and that no handouts are permitted. Presenters are requested to sign in at least 10 minutes prior to start of meeting.

Ms. Kirby stated that any documents used in the meeting that are not marked confidential and proprietary will be posted on DOM's website (www.medicaid.ms.gov) after the meeting.

Ms. Kirby reviewed policies related to food and drink, cell phones and laptop usage, discussions in the hallways, and emergency procedures for the building.

Ms. Kirby stated that DOM aggressively pursues supplemental rebates. Mississippi is part of the Sovereign States Drug Consortium (SSDC) pool.

Ms. Kirby reviewed the voting procedure and reminded the Committee that, in accordance with the Mississippi Open Meetings Act, the minutes reflect each person's vote. She requested that the Chair announce the recommendation, motions, and the names of committee members making motions. The minutes for each P&T Committee meeting are posted to the DOM website (www.medicaid.ms.gov) within 30 days of the meeting. The meeting minutes will be posted no later than December 1, 2017. Decisions will be announced no later than December 1, 2017 on the DOM website.

Ms. Kirby stated that the P&T Committee works in an advisory capacity and that DOM is responsible for final decisions related to the PDL. She reviewed the meeting process. She stated that DOM takes into account recommendations from both the P&T Committee and the clinical contractor before making a final decision. She stated that the PDL is completely updated once per year; quarterly updates are implemented throughout the year.

Ms. Kirby reviewed Committee policies and procedures. She requested that Committee members complete their travel vouchers and reviewed the contents of the folders provided to each Committee member.

IV. Division of Medicaid Update

Ms. Kirby stated that the new pharmacy reimbursement methodology went into place September 1, 2017. She also stated that the reprocessing of claims with a date of service from April 1, 2017- August 31, 2017, began October 1, 2017.

V. Approval of August 8, 2017 Meeting Minutes

Ms. Wilbanks asked for additions or corrections to the minutes from the August 8, 2017 meeting. There were no further additions or corrections. The minutes stand approved as corrected.

VI. PDL Compliance/Generic Percent Report Updates

Dr. Clayton provided an explanation of the PDL Compliance and Generic Percent reports.

- a. Dr. Clayton reviewed the PDL Compliance Report; overall compliance for Q3 2017 was 97.7%.
- b. Dr. Clayton reviewed the Generic Percent Report; overall generic utilization for Q3 2017 was 86.9%.

VII. Drug Class Announcements

Dr. Bissell reviewed the meeting format.

VIII. First Round of Extractions

CHC recommended that the following classes be extracted:

- Glucocorticoids (Inhaled)
- Hepatitis C Treatments
- Hypoglycemics, Insulins and Related Agents
- IBS/SBS/Selected GI Agents
- Miscellaneous Brand/Generic
- NSAIDS
- Platelet Aggregation Inhibitors
- Stimulants & Related Agents

IX. Public Comments

Zulma Schlossberg from Tris Pharma spoke in favor of Dynavel.

Jason Swartz from Otsuka spoke in favor of Rexulti.

Shannon Sands from Sunovion spoke in favor of Utibron.

Brandon Young from Pfizer spoke in favor of Xeljanz.

Sunil Majethia from Gilead Sciences spoke in favor of Vosevi.

Alice Kelly Morgan from Pfizer spoke in favor of Eucrisa.

Yvonne Luu from Teva spoke in favor of Copaxone and Austedo.

X. Second Round of Extractions

Dr. Weiland asked that the Atopic Dermatitis be extracted.

XI. Non-Extracted Categories

CHC recommended that the following list be approved without extraction.

- Acne Agents
- Alpha 1-Proteinase Inhibitors
- Alzheimer's Agents
- Analgesics, Narcotics- Short Acting
- Analgesics, Narcotics-Long Acting
- Analgesics/Anesthetics (Topical)
- Androgenic Agents
- Angiotensin Modulators

- Antibiotics (GI)
- Antibiotics (Miscellaneous)
- Antibiotics (Topical)
- Antibiotics (Vaginal)
- Anticoagulants
- Anticonvulsants
- Antidepressant-Other
- Antidepressants- SSRIs
- Antiemetics
- Antifungals (Oral)
- Antifungals (Topical)
- Antifungals (Vaginal)
- Antihistamines, Minimally Sedating & Combinations
- Antimigraine Agents, Triptans
- Antineoplastics- Selected Systemic Enzyme Inhibitors
- Antiparasitics (Topical)
- Antiparkinson's Agents (Oral)
- Antipsychotics
- Antivirals (Oral)
- Antivirals (Topical)
- Aromatase Inhibitors
- Beta Blockers
- Bile Salts
- Bladder Relaxant Preparations
- Bone Resorption Suppression & Related Agents
- BPH Agents
- Bronchodilators & COPD Agents
- Bronchodilators, Beta Agonists
- Calcium Channel Blockers
- Cephalosporins & Related Antibiotics (Oral)
- Cystic Fibrosis Agents
- Colony Stimulating Factors
- Cytokine & Cam Antagonists
- Erythropoiesis Stimulating Proteins
- Fibromyalgia Agents
- Fluoroquinolones (Oral)
- Genital Warts & Related Agents
- GI Ulcer Therapies
- Growth Hormones
- Gaucher's Disease
- H. Pylori Combination Treatments
- Hepatitis B Treatments
- Hyperuricemia & Gout
- Hypoglycemics, Incretin Mimetics/Enhancers
- Hypoglycemics, Meglitinides

- Hypoglycemics, Sodium Glucose Cotransporter-2 Inhibitors
- Hypoglycemics, TZDs
- Idiopathic Pulmonary Fibrosis
- Immune Globulins
- Immunosuppressive (Oral)
- Intranasal Rhinitis Agents
- Iron Chelating Agents
- Leukotriene Modifiers
- Lipotropics, Other (Non-Statins)
- Lipotropics, Statins
- Movement Disorder Agents
- Multiple Sclerosis Agents
- Ophthalmic Antibiotics
- Ophthalmic Anti-inflammatories
- Ophthalmics for Allergic Conjunctivitis
- Ophthalmics, Glaucoma Agents
- Opiate Dependence Treatments
- Otic Antibiotics
- Pancreatic Enzymes
- Parathyroid Agents
- Phosphate Binders
- Prenatal Vitamins
- Pseudobulbar Affect Agents
- Pulmonary Antihypertensives
- Sedative Hypnotics
- Select Contraceptive Products
- Skeletal Muscle Relaxants
- Smoking Deterrents
- Steroids (Topical)
- Tetracyclines
- Ulcerative Colitis & Crohn's Agent

Dr. Weiland moved to accept the recommendations. Dr. Hartness seconded. Votes were taken, and the motion was adopted.

XII. Extracted Therapeutic Class Reviews

a. Atopic Dermatitis

Dr. Weiland asked to discuss the potential inclusion for Eucrisa to the preferred agents. A robust clinical and financial discussion followed. The motion to accept the CHC recommendation was made by Dr. Weiland. Seconded by Dr. Parham. Votes were taken, and the motion was accepted. The category will have no changes.

b. Glucocorticoids (Inhaled)

CHC recommended that the following list be approved. A robust clinical discussion followed. Dr. Minor moved to accept the recommendation. Dr. Weiland seconded. Votes were taken, and the motion was adopted. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
GLUCOCORTICIDS	
budesonide 0.25mg and 0.5mg PULMICORT (budesonide) Flexhaler	AEROSPAN (flunisolide) ALVESCO (ciclesonide) ARMONAIR RESPICLICK (fluticasone) ARNUITY ELLIPTA (fluticasone) ASMANEX TWISTHALER (mometasone) ASMANEX HFA (mometasone) budesonide 1mg FLOVENT Diskus (fluticasone) FLOVENT HFA (fluticasone) PULMICORT (budesonide) Respules QVAR (beclomethasone dipropionate) QVAR Redihaler (betamethasone dipropionate)
GLUCOCORTICOID/BRONCHODILATOR COMBINATIONS	
ADVAIR Diskus (fluticasone/salmeterol) ADVAIR HFA (fluticasone/salmeterol) DULERA (mometasone/formoterol) SYMBICORT (budesonide/formoterol)	AIRDUO Resplick (fluticasone/salmeterol) BREO ELLIPTA (fluticasone/vilanterol)

c. Hepatitis C Treatments

CHC recommended that the following list be approved. A robust clinical discussion followed. Dr. Sullivan moved to accept the recommendation. Dr. Parham seconded. Votes were taken, and the motion was adopted. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
EPCLUSA (sofosbuvir/velpatasvir) ∞ MAVYRET (glecaprevir/pibrentasvir) ∞ PEGASYS (peginterferon alfa-2a) PEG-INTRON (peginterferon alfa-2b) ribavirin tablets ZEPATIER (elbasvir/grazoprevir) ∞	DAKLINZA (daclatasvir) ∞ HARVONI (ledipasvir/sofosbuvir) ∞ OLYSIO (simeprevir) ∞ REBETOL (ribavirin) RIBAPAK DOSEPACK (ribavirin) ribavirin capsules RIBASPHERE (ribavirin) SOVALDI (sofosbuvir) ∞ TECHNIVIE (ombitasvir/paritaprevir/ritonavir) ∞ VIEKIRA (ombitasvir/paritaprevir/ritonavir) ∞ VIEKIRA XR (ombitasvir/paritaprevir/ritonavir) ∞ VOSEVI (sofosbuvir/velpatasvir/voxilaprevir) ∞

d. Hypoglycemics, Insulins & Related Agents

CHC recommended that the following list be approved. A robust clinical discussion followed. Dr. Minor moved to accept the recommendation. Dr. Weiland seconded. Votes were taken, and the motion was adopted. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
HUMALOG VIAL (insulin lispro) HUMALOG MIX VIAL (insulin lispro/ lispro protamine) HUMULIN VIAL (insulin) LANTUS SOLOSTAR & VIAL (insulin glargine) LEVEMIR FLEXPEN & VIAL (insulin detemir)	AFREZZA (insulin) APIDRA (insulin glulisine) BASAGLAR (insulin glargine) HUMALOG JR (insulin lispro) HUMALOG KWIKPEN (insulin lispro) HUMALOG MIX KWIKPEN (insulin lispro/ lispro protamine) HUMULIN KWIKPEN (insulin) NOVOLIN FLEXPEN (insulin) NOVOLIN VIAL (insulin) NOVOLOG FLEXPEN & VIAL (insulin aspart) NOVOLOG MIX FLEXPEN & VIAL (insulin aspart/ aspart protamine) TOUJEO (insulin glargine) TRESIBA (insulin degludec)

e. IBS/SBS/Selected GI Agents

CHC recommended that the following list be approved. A robust clinical discussion followed. Dr. Weiland moved to accept the recommendation. Dr. Cook seconded. Votes were taken, and the motion was adopted. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
IRRITABLE BOWEL SYNDROME CONSTIPATION	
AMITIZA (lubiprostone) LINZESS (linaclotide)	MOVANTIK (naloxegol) RELISTOR (methylnaltrexone) ∞ TRULANCE (plecanatide)
IRRITABLE BOWEL SYNDROME DIARRHEA	
dicyclomine hyoscyamine VIBERZI (eluxadoline)	alosetron∞ BENTYL (dicyclomine) LEVSIN (hyoscyamine) LEVSIN-SL (hyoscyamine) LOTRONEX (alosetron) ∞
SHORT BOWEL SYNDROME AND SELECTED GI AGENTS	
	FULYZAQ (crofelemer) ∞ GATTEX (teduglutide) MYTESI (crofelemer) NUTRESTORE POWDER PACK (glutamine) XERMELO (telotristat ethyl)

PREFERRED AGENTS	NON-PREFERRED AGENTS
	ZORBTIVE (somatropin) ∞

f. Miscellaneous Brand/Generic

CHC recommended that the following list be approved. A robust clinical discussion followed. Dr. Weiland moved to accept the recommendation. Dr. Parham seconded. Votes were taken, and the motion was adopted. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
CLONIDINE	
CATAPRES-TTS (clonidine) clonidine tablets	clonidine patches CATAPRES (clonidine)
EPINEPHRINE	
epinephrine autoinject pens (labeler 49502)	ADRENACLICK (epinephrine) AUVI-Q (epinephrine) EPIPEN (epinephrine) EPIPEN JR (epinephrine)
MISCELLANEOUS	
alprazolam hydroxyzine hcl syrup hydroxyzine pamoate MAKENA (hydroxyprogesterone caproate) megestrol suspension 625mg/5mL	alprazolam ER ^{SmartPA} hydroxyzine hcl tablets KORLYM (mifepristone) MEGACE ES (megestrol) VISTARIL (hydroxyzine pamoate)
SUBLINGUAL ALLERGEN EXTRACT IMMUNOTHERAPY	
	GRASTEK ORALAIR RAGWITEK
SUBLINGUAL NITROGLYCERIN	
nitroglycerin lingual 12gm nitroglycerin sublingual NITROLINGUAL PUMPSPRAY (nitroglycerin) 12gm NITROSTAT SUBLINGUAL (nitroglycerin)	nitroglycerin lingual 4.9gm NITROLINGUAL (nitroglycerin) 4.9gm NITROMIST (nitroglycerin)

g. NSAIDS

CHC recommended that the naproxen 275mg and 550mg strengths be non-preferred as a cost savings initiative. A financial discussion followed. Dr. Minor moved to accept the recommendation. Dr. Weiland seconded. Votes were taken, and the motion was adopted.

h. Platelet Aggregation Inhibitors

CHC recommended that the recommendation below not be accepted based on the fact that, as of the meeting date, the price of prasugrel has remained high and it is not cost effective to the State. A motion was not passed and no changes will be made for this category. CHC reminded

the Board that DOM had the right to make generic/brand PDL changes and that this matter will continue to be monitored as to when the switch will be cost effective to the State.

PREFERRED AGENTS	NON-PREFERRED AGENTS
AGGRENOX (dipyridamole/aspirin) BRILINTA (ticagrelor) cilostazol clopidogrel dipyridamole pentoxifylline prasugrel	DURLAZA (aspirin) EFFIENT (prasugrel) PERSANTINE (dipyridamole) PLAVIX (clopidogrel) PLETAL (cilostazol) ticlopidine ZONTIVITY (vorapaxar) <small>Clinical Edit</small>

i. Stimulants & Related Agents

CHC recommended that the following list be approved. A robust clinical discussion followed. Dr. Hartness moved to accept the recommendation. Dr. Weiland seconded. Votes were taken, and the motion was adopted. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
SHORT-ACTING	
amphetamine salt combination dexmethylphenidate IR FOCALIN (dexmethylphenidate) METHYLIN chewable tablets (methylphenidate) METHYLIN solution (methylphenidate) methylphenidate IR PROCENTRA (dextroamphetamine)	ADDERALL (amphetamine salt combination) DESOXYN (methamphetamine) dextroamphetamine IR dextroamphetamine solution EVEKEO (amphetamine) methamphetamine methylphenidate chewable methylphenidate solution ZENZEDI (dextroamphetamine)
LONG-ACTING	
amphetamine salt combination ER APTENSIO XR (methylphenidate) armodafinil FOCALIN XR (dexmethylphenidate) methylphenidate CD (generic Metadate CD) methylphenidate ER (generic Concerta; labelers 00591, 62175 & 68084) modafinil QUILLICHEW (methylphenidate) QUILLIVANT XR (methylphenidate) VYVANSE (lisdexamfetamine) VYVANSE CHEWABLE(lisdexamfetamine)	ADDERALL XR (amphetamine salt combination) ADZENYS XR ODT (amphetamine) CONCERTA (methylphenidate) COTEMPLA XR-ODT (methylphenidate) ^{NR} DAYTRANA (methylphenidate) DEXEDRINE (dextroamphetamine) dexmethylphenidate ER dextroamphetamine ER DYANAVEL XR (amphetamine) methylphenidate ER Caps (generic Ritalin LA) methylphenidate ER Tabs (generic Ritalin SR) MYDAYIS (amphetamine salt combination) NUVIGIL (armodafinil) PROVIGIL (modafinil) RITALIN LA (methylphenidate) RITALIN SR (methylphenidate)

PREFERRED AGENTS	NON-PREFERRED AGENTS
NON-STIMULANTS	
atomoxetine guanfacine ER Step Edit	clonidine ER INTUNIV (guanfacine ER) KAPVAY (clonidine extended-release) STRATTERA (atomoxetine)

XIII. Other Business

a. Election of Chairperson

The floor was opened for nominations for Chairman. Mrs. Wilma Wilbanks was nominated by Dr. Weiland, seconded by Dr. Hartness. Nominations were closed and Mrs. Wilbanks was unanimously reelected Chairman.

b. Election of Vice Chairperson

The floor was opened for nominations for Vice Chairman. Dr. Deborah Minor was nominated by Dr. Parham, seconded by Dr. Sullivan. Nominations were closed and Dr. Minor was unanimously elected Vice Chairman.

XIV. Next Meeting Date

The next meeting of the Pharmacy & Therapeutics Committee will be held on February 13, 2018 at 10:00 a.m. in the Woolfolk Building, Conference Center East, Room 145, in Jackson, Mississippi.

XV. Adjournment

The meeting adjourned at 11:56 a.m.